©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Functional Organization of Mammalian Hexokinase II
RETENTION OF CATALYTIC AND REGULATORY FUNCTIONS IN BOTH THE NH(2)- AND COOH-TERMINAL HALVES (*)

(Received for publication, November 9, 1995; and in revised form, December 1, 1995)

Hossein Ardehali (1)(§) Yutaka Yano (1)(¶) Richard L. Printz (1) Steve Koch (1) Richard R. Whitesell (1) James M. May (1) (2) Daryl K. Granner (1) (2)(**)

From the  (1)Departments of Molecular Physiology and Biophysics and (2)Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The mammalian hexokinase (HK) family includes three closely related 100-kDa isoforms (HKI-III) that are thought to have arisen from a common 50-kDa precursor by gene duplication and tandem ligation. Previous studies of HKI indicated that a glucose 6-phosphate (Glu-6-P)-regulated catalytic site resides in the COOH-terminal half of the molecule and that the NH(2)-terminal half contains only a Glu-6-P binding site. In contrast, we now show that proteins representing both halves of human and rat HKII have catalytic activity and that each is inhibited by Glu-6-P. The intact enzyme and the NH(2)- and COOH-terminal halves of the enzyme each increase glucose utilization when expressed in Xenopus oocytes. Mutations corresponding to either Asp-209 or Asp-657 in the intact enzyme completely inactivate the NH(2)- and COOH-terminal half enzymes, respectively. Mutation of either of these sites results in a 50% reduction of activity in the 100-kDa enzyme. Mutation of both sites results in a complete loss of activity. This suggests that each half of the HKII molecule retains catalytic activity within the 100-kDa protein. These observations indicate that HKI and HKII are functionally distinct and have evolved differently.


INTRODUCTION

The four mammalian hexokinases (ATP:D-hexose-6-phosphotransferase, EC 2.7.1.1) initiate glucose metabolism by catalyzing the conversion of glucose to glucose 6-phosphate (Glu-6-P). (^1)Hexokinases I-III (HKI-III) have a molecular mass of 100 kDa, a high affinity for glucose, and are feedback-inhibited by physiologic concentrations of Glu-6-P. Glucokinase (HKIV or GK), a 50-kDa protein with a lower affinity for glucose, is not inhibited by physiologic concentrations of Glu-6-P, nor is the 50-kDa yeast enzyme. The 100-kDa isoforms are thought to have arisen from a 50-kDa precursor through gene duplication and tandem ligation(1) . The high degree of amino acid similarity between the NH(2)- and COOH-terminal halves of a given HK with each other, with yeast HK, and with GK, supports this hypothesis(2, 3, 4) . Additional support for a gene duplication event is provided by the demonstration of exon size conservation between GK and the NH(2)- and COOH-terminal halves of HKII and by localization of the likely fusion site within the HKII gene(5, 6) .

Analysis of the functional domains of the hexokinases has also been performed to learn how these enzymes evolved. Glucose and ATP bind to the COOH-terminal half of the 100-kDa HKI molecule, whereas Glu-6-P binds to the NH(2)-terminal half(7, 8, 9, 10) . If a yeast-like HK is the precursor, it is necessary to hypothesize that the catalytic site is retained in the COOH half, but is lost in the NH(2) half of HKI and replaced by a regulatory site(1) . The two halves of the HKI molecule have been obtained by proteolytic cleavage (11) and by construction of cDNA-based vectors that direct their expression (12, 13) . As predicted from studies of the intact molecule, the COOH-terminal half of HKI is catalytically active, and the NH(2)-terminal half is not(11, 12, 13) . However, the observation that the COOH-terminal half is inhibited by Glu-6-P was not expected based on the behavior of the intact enzyme(11, 13) . In view of these observations, a 50-kDa precursor with both catalytic and regulatory sites, such as exists in various marine organisms, silkworms, and schistosomes(14, 15, 16, 17) , could have been duplicated to form the 100-kDa hexokinases(11, 13) . If so, the catalytic site in intact HKI must be lost or occluded in the NH(2)-terminal half and retained in the COOH-terminal half, whereas the regulatory site could involve either or both halves. Although it is assumed that all of the 100-kDa hexokinases evolved similarly, and that they share structural and functional features, only the HKI isoform has been analyzed in detail. We show here that the NH(2)- and COOH-terminal halves of rat and human HKII (N-HKII and C-HKII) both have catalytic activity in the intact enzyme and when expressed as discrete proteins. In addition, both halves of HKII are inhibited by Glu-6-P. These observations support the hypothesis that a 50-kDa precursor with both catalytic and regulatory sites was duplicated to form the 100-kDa hexokinases, and that HKII retains more of the characteristics of the ancestral gene than does HKI.


EXPERIMENTAL PROCEDURES

Expression and Purification of Fusion Proteins

The pGef plasmid, constructed by insertion of a bacteriophage f1 origin into the pGex-3x vector (Pharmacia Biotech Inc.), was linearized at a SmaI restriction site located adjacent to the glutathione S-transferase (GST) cDNA. The cDNAs encoding human HKII, N-HKII, and C-HKII (18, 19) were then ligated into pGef to obtain pGSTbulletHKII, pGSTbulletN-HKII, and pGSTbulletC-HKII plasmids, respectively. pGSTbulletN-HKII encodes amino acids 1-469, and pGSTbulletC-HKII contains the coding sequence for amino acids 470-917 of human HKII. Escherichia coli, XL-1 Blue strain (Stratagene), were transformed with the recombinant plasmid and were grown to an A of 0.6 in LB medium containing 200 µg/ml ampicillin. Isopropyl-1-thio-beta-D-galactopyranoside was added to a final concentration of 0.4 mM, and the cells were incubated at ambient temperature for 4 h. Cells were collected by centrifugation (4,400 times g for 10 min at 4 °C) and resuspended in HB buffer (50 mM triethanolamine, pH 7.3, 50 mM KCl, 10 mM glucose, 1 mM dithiothreitol) plus protease inhibitors (1 µg/ml leupeptin, 1 µg/ml pepstatin A, 1 mM benzamidine, 1 mM EDTA, 1 mM EGTA, and 1 mM phenylmethanesulfonyl fluoride). The resuspended cells were then sonicated at 4 °C for 20 s, and the bacterial lysates were cleared of cellular debris by centrifugation (12,000 times g for 5 min at 4 °C). The bacterial extract containing the fusion protein was applied directly to glutathione-Sepharose 4B (Pharmacia). The mixture was allowed to incubate at 4 °C for 1 h. The suspension was centrifuged (12,000 times g for 1 min at 4 °C), and the pellet was washed twice in 15 bed volumes of a HB buffer including the protease inhibitors and twice in 15 bed volumes of HB buffer. The fusion proteins were then eluted from the column with 0.75 ml of HB buffer containing 10 mM reduced glutathione. The eluted proteins were assayed for hexokinase activity as described below and were visualized on 7% SDS-polyacrylamide gels.

Polymerase Chain Reaction (PCR)-based Mutagenesis of Hexokinase II

Site-directed mutations were generated by two separate PCR reactions with pGSTbulletHKII plasmid DNA as a template. To generate D209A, the primer A1943 (5`-GGTCCCAACTGTGGCATTCACCACAGCC-3`, the underlined letters here and below indicate base substitutions) and an upstream HKII specific primer C1474 (5`-GGTCCCAACTGTGGCATTCACCACAGCC-3`) were used to amplify a 720-base pair (bp) segment of the human cDNA with the desired mutation. A second PCR was performed using a primer A2083 that is the reverse complement of A1943 and a downstream HKII specific primer A680 (5`-TGTTGATCGGCCAGCCGG-3`) to amplify a 785-bp segment, whose first 28 bp are identical to the 3` end of the first PCR product. Equal amounts of the two purified PCR products were mixed, denatured and annealed, and used as a template for a third PCR reaction with primers C1474 and A680 to generate a 1477-bp product with the desired amino acid changes. The final PCR product was digested with BamHI and SalI and was used to replace the wild type BamHI-SalI restriction fragment in pGSTbulletHKII plasmid.

To construct D657A, primers C477 (5`-CATTGTCCAGTGCATCGC-3`) and C1191 (5`-AGTTCCGACTGTGGCGTTCACCACAGCA-3`) were used in the first PCR reaction, and primers A2084 (reverse complement of C1191) and B1046 (5`-TCTGAGACAAGAACTTGG-3`) were used in the second PCR reaction. The third PCR product was digested with XhoI and ClaI and cloned into pGSTbulletHKII. The PCR fragments inserted into pGSTbulletHKII were validated by DNA sequencing.

Glucose Phosphorylation Assays

The K(m) values for glucose and ATP of HKII enzymes were determined by measuring the phosphorylation of [U-^14C]glucose as a function of added glucose (0.1-3 mM) and ATP (0.2-10 mM). The apparent K(i) values for Glu-6-P were determined, with Glu-6-P ranging from 0 to 10 mM, at a glucose concentration of 0.1 mM and an ATP concentration of 10 mM for D209A and D657A and 5 mM for the other enzymes. An aliquot (5-10 µl) of purified protein was added to 90 µl of assay buffer containing 50 mM triethanolamine, pH 7.3, 20 mM MgCl(2), 100 mM KCl, 1 mM dithiothreitol, and 0.05 µCi of [U-^14C]glucose. After an incubation of 30 min at ambient temperature, the reaction was terminated with the addition of 200 µl of isopropyl alcohol. The [U-^14C]Glu-6-P produced was isolated and quantified as described previously(20) . The rate of glucose phosphorylation was linear during the assay, and the concentration of Glu-6-P at the termination of the assay was less than 0.1 mM (when not added to the assay; results not shown). The kinetic parameters were determined for each experiment by nonlinear least-squares regression using an equation for substrate affinity or noncompetitive inhibition(21) . The specific activity of the human enzymes, corrected for the contribution of the GST protein, was measured using a Glu-6-P dehydrogenase/NADP-coupled assay (22) . In this case, 1 unit of HK activity is defined as the amount required to produce 1 µmol of Glu-6-P in 1 min at 37 °C.

Oocyte Studies

The expression of GLUT3 mRNA in Xenopus laevis oocytes was performed as described previously (23) . Wild type and mutant rat mRNAs were obtained by using the Stratagene In Vitro Transcription Kit and rat HKII cDNA as the template(6) . Oocytes were injected with 15 ng of GLUT3 mRNA with or without either 50 ng of HKII mRNA, 35 ng of C-HKII mRNA (encoding amino acids 469-917), or 25 ng of N-HKII mRNA (encoding amino acids 1-468). Co-expression of the rat HKIIs with GLUT3 had no effect on the rate of 3-O-methylglucose uptake (data not shown). Coupled transport and phosphorylation of glucose was measured by incubating oocytes in [2-^3H]glucose with quantitation of ^3H(2)O released(23) . Protein extracts were obtained from 10 oocytes and were assayed for hexokinase activity (see above).


RESULTS AND DISCUSSION

The NH(2)- and COOH-terminal Halves of Human and Rat HKII Are Catalytically Active

The availability of the human HKII cDNA (18, 19) allowed us to test the N- and C-terminal halves of this isoform directly for activity. GST fusion proteins of intact HKII, N-HKII, and C-HKII were expressed in E. coli and purified to homogeneity (Fig. 1). The kinetic properties of these three proteins are shown in Table 1. The specific activities of human N-HKII and C-HKII, although less than that measured for the intact enzyme, are comparable. All three enzymes had similar K(m) values for glucose, but C-HKII had a significantly lower affinity for ATP and Glu-6-P than did the other enzymes. Based on this experiment, we conclude that N-HKII and C-HKII are both active enzymes.


Figure 1: SDS-polyacrylamide gel electrophoresis of affinity-purified GST fusion proteins. Each HKII fusion protein was expressed and purified as described under ``Experimental Procedures.'' The proteins were stained with Coomassie Blue to illustrate the purity of a representative preparation of N-HKII, C-HKII and HKII used to obtain the kinetic data shown in Table 1. The lanes on the left illustrate the relative level of fusion protein before purification in the crude extracts. The molecular masses of the protein standards are indicated on the left (in kDa) and the estimated mass of each purified fusion protein is shown on the right. The GSTbulletHKII fusion protein has an expected mass of 130 kDa, GSTbulletN-HKII of 80 kDa, and GSTbulletC-HKII of 76 kDa.





The purification of the human enzymes involved the binding of the GST fusion protein to a glutathione affinity column (Fig. 1). To evaluate whether the GST addition altered the kinetic properties of any of the enzymes, and to check for possible species differences, the mRNAs encoding the intact molecule, as well as the N- and C-terminal halves of rat HKII, were injected into X. laevis oocytes, and HK activity in the cell extracts was measured. In this cell-based system, as with the purified human HKII proteins, both the NH(2)- and COOH-terminal halves of rat HKII actively phosphorylate glucose (Table 2). The kinetic parameters determined for the rat enzymes are similar to those observed for the human enzymes ( Table 1and Table 2); thus, the GST addition does not appear to affect the enzymes. The N-HKII and intact enzymes of both species have significantly higher affinities for ATP and Glu-6-P than does C-HKII. In addition, the intact HKII enzymes from both human and rat have kinetic parameters that resemble those previously observed in rat skeletal muscle, in which HKII is known to be the predominant isoform ( (24) and Table 1and Table 2).



No hexokinase activity was observed in extracts obtained after the injection of mRNAs encoding either N-HKII or C-HKII with a single Asp to Ala substitution (corresponding to Asp-209 and Asp-657 in intact HKII) into oocytes (data not shown). These results identify Asp-209 and Asp-657 as critical residues in the catalytic sites of N- and C-HKII, respectively, as is the corresponding amino acid in GK (Asp-205) and the single, COOH-terminal catalytic site in HKI (Asp-657)(13, 25) .

Having identified a single amino acid mutation that results in the loss of activity of rat N-HKII and C-HKII, we constructed mutated human HKIIs to evaluate whether the NH(2)- and COOH-halves are each active in the context of the intact 100-kDa enzyme. Individual Asp-209 or Asp-657 Ala mutations (D209A and D657A proteins, respectively) should result in a partial loss of activity if both halves of HKII are catalytically active in the intact enzyme. Moreover, an HKII protein with mutations in both halves (D209A + D657A) should be inactive. These mutant HKII proteins were expressed as GST fusion proteins and purified as described for the wild type enzyme. The double mutation resulted in a complete loss of catalytic activity (D209A + D657A in Table 3). A single mutation in either the NH(2)- or COOH-terminal half of HKII (D209A or D657A, respectively) resulted in about a 50% reduction as compared to the wild type enzyme (84 or 71 versus 147 units/mg, Table 1and Table 3). The D209A and D657A mutants have K(m) values for glucose comparable to those of HKII, N-HKII, and C-HKII (see Table 1and Table 3). D657A has a K(m) for ATP similar to that of HKII and N-HKII ( Table 1and Table 3). The D209A enzyme has a lower K(m) for ATP compared with that of C-HKII, but it is still significantly higher than that of HKII ( Table 1and Table 3). These results suggest that the NH(2)- and COOH-terminal halves of HKII are active enzymes in the intact protein, and that the activity of the whole enzyme may be a combination of the activities of both halves.



Analysis of the NH(2)- and COOH-terminal Halves of HKII in an Intact Cell

To confirm that the various HKII proteins are functional in an intact cell, the mRNAs encoding either rat HKII, N-HKII, or C-HKII were injected into X. laevis oocytes and glucose phosphorylation was measured in situ as the rate of glucose utilization (^3H(2)O release from [2-^3H]glucose). Each hexokinase increased glucose utilization at the two highest glucose concentrations (Fig. 2); the apparent K(m) and V(max) values for in situ glucose utilization are provided in the inset to Fig. 2. In this context, N-HKII is as active as C-HKII or the intact enzyme, and the K(m) values for glucose are comparable. It should be noted that these K(m) values are higher than those determined using the oocyte extracts (see Table 2), which may reflect less than optimal access of glucose to the hexokinase due to limited transport or intracellular compartmentalization of the substrate. These results demonstrate that each HKII protein is active when expressed in an intact cell and each, in conjunction with the glucose transporter, results in increased glucose utilization by the cell.


Figure 2: The HKII proteins expressed in X. laevis oocytes increase cellular glucose phosphorylation. ^3H(2)O production from [2-^3H]glucose was measured in 7-10 oocytes at the indicated glucose concentrations 2 days after the injection of oocytes with GLUT3 mRNA with or without HKII mRNAs. Glucose utilization of water-injected oocytes was subtracted, at each glucose concentration, from utilization measured in oocytes expressing the various proteins. The results are presented as the mean + S.E. of six experiments. Shown in the inset are the apparent K and V(max) values for glucose utilization.



Glu-6-P Regulates the NH(2)- and COOH-terminal Halves of Human and Rat HKII

The demonstration that both halves of HKII are catalytically active distinguishes this enzyme from HKI in which only the COOH half is active(11, 12, 13) . The expressed COOH half of HKI is inhibited by Glu-6-P and has a K(i) value similar to that of the intact enzyme(11) . However, both expressed halves of HKI bind Glu-6-P(13) , and Glu-6-P binds with higher affinity to the NH(2) half of HKI in the intact enzyme(9, 10) . Thus, the mechanism of Glu-6-P inhibition in the intact HKI enzyme remains unclear. It was therefore of interest to determine whether each half of HKII is inhibited by Glu-6-P. As illustrated in Table 1and Table 2, human and rat HKII and N-HKII and rat skeletal muscle HKII(24) , all have comparable apparent K(i) values for Glu-6-P. The human and rat C-HKII enzymes have a significantly higher K(i) for Glu-6-P when compared to HKII and N-HKII. Also, as shown in Table 3, D657A has a K(i) value similar to that observed for HKII and N-HKII, whereas D209A has a significantly higher K(i) value than either HKII or C-HKII. Thus, although both halves of HKII are sensitive to Glu-6-P inhibition, the NH(2) half most resembles the intact enzyme.

The present model for the evolution of hexokinases, based on studies with HKI, suggests that HKI-III evolved by duplication of a gene encoding a 50-kDa, Glu-6-P-sensitive hexokinase. As a consequence of the duplication process, the regulatory site in the COOH half and the catalytic site in the NH(2) half of the 100-kDa HKs are lost or masked. The observation that both the NH(2)- and COOH-terminal halves of HKII have catalytic and Glu-6-P regulatory functions necessitates a re-evaluation of this hypothesis, at least as regards this isoform.

The results presented here suggest that HKII possesses properties that may allow it to play unique roles in glucose metabolism under different physiological conditions. According to this hypothesis, each half of HKII may respond to Glu-6-P levels differently since each has distinct K(i) values for Glu-6-P. In addition, the two halves of HKII are likely to show different activities over a range of intracellular ATP concentrations. Therefore, although the NH(2)- and COOH-terminal halves of HKII carry out the same basic reaction in the intact enzyme, they may respond differently to substrate and inhibitor concentrations. These intriguing properties of HKII and their possible physiological significance warrant further investigation.


FOOTNOTES

*
This work was supported in part by Department of Health and Human Services Grants DK46867 and DK19925 and Vanderbilt Diabetes Research and Training Center Grant DK20593. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Supported by Vanderbilt Medical Scientist Training Program GM07347.

Present address: Third Department of Internal Medicine, Mie University School of Medicine, Japan.

**
To whom correspondence should be addressed: Dept. of Molecular Physiology and Biophysics, 707 Light Hall, Vanderbilt University School of Medicine, Nashville, TN 37232. Tel.: 615-322-7004; Fax: 615-322-7236; :daryl.granner{at}mcmail.vanderbilt.edu.

(^1)
The abbreviations used are: Glu-6-P, glucose 6-phosphate; HK, hexokinase; GK, glucokinase; N-, NH(2)-; C-, COOH; GST, glutathione S-transferase; PCR, polymerase chain reaction; bp, base pair(s); ANOVA, analysis of variance.


ACKNOWLEDGEMENTS

We thank D. Caplenor for her assistance with the preparation of this manuscript.


REFERENCES

  1. Wilson, J. E. (1995) Rev. Physiol. Biochem. Pharmacol. 126, 65-198 [Medline] [Order article via Infotrieve]
  2. Schwab, D. A., and Wilson, J. E. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 2563-2567 [Abstract]
  3. Frohlich, K. U., Entian, K. D., and Mecke, D. (1985) Gene (Amst.) 36, 105-111 [Medline] [Order article via Infotrieve]
  4. Andreone, T. L., Printz, R. L., Pilkis, S. J., Magnuson, M. A., and Granner, D. K. (1989) J. Biol. Chem. 264, 363-369 [Abstract/Free Full Text]
  5. Magnuson, M. A., Andreone, T. L., Printz, R. L., Koch, S., and Granner, D. K. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 4838-4842 [Abstract]
  6. Printz, R. L., Koch, S., Potter, L. R., O'Doherty, R. M., Tiesinga, J. J., Moritz, S., and Granner, D. K. (1993) J. Biol. Chem. 268, 5209-5219 [Abstract/Free Full Text]
  7. Schirch, D. M., and Wilson, J. E. (1987) Arch. Biochem. Biophys. 254, 385-396 [Medline] [Order article via Infotrieve]
  8. Nemat-Gorgani, M., and Wilson, J. E. (1986) Arch. Biochem. Biophys. 251, 97-103 [Medline] [Order article via Infotrieve]
  9. White, T. K., and Wilson, J. E. (1987) Arch. Biochem. Biophys. 259, 402-411 [Medline] [Order article via Infotrieve]
  10. White, T. K., and Wilson, J. E. (1990) Arch. Biochem. Biophys. 277, 26-34 [Medline] [Order article via Infotrieve]
  11. White, T. K., and Wilson, J. E. (1989) Arch. Biochem. Biophys. 274, 375-393 [Medline] [Order article via Infotrieve]
  12. Baijal, M., and Wilson, J. E. (1992) Arch. Biochem. Biophys. 298, 271-278 [Medline] [Order article via Infotrieve]
  13. Arora, K. K., Filburn, C. R., and Pedersen, P. L. (1993) J. Biol. Chem. 268, 18259-18266 [Abstract/Free Full Text]
  14. Mochizuki, Y. (1981) Comp. Biochem. Physiol. 70B, 745-751
  15. Mochizuki, Y., and Hori, S. H. (1977) J. Biochem. (Tokyo) 81, 1849-1855 [Abstract]
  16. Yanagawa, H. A. (1978) Insect Biochem. 8, 293-305
  17. Tielens, A. G. M., Van den Heuvel, J. M., Jan Van Mazijk, H., Wilson, J. E., and Shoemaker, C. B. (1994) J. Biol. Chem. 269, 24736-24741 [Abstract/Free Full Text]
  18. Deeb, S. S., Malkki, M., and Laakso, M. (1993) Biochem. Biophys. Res. Commun. 197, 68-74 [CrossRef][Medline] [Order article via Infotrieve]
  19. Printz, R. L., Ardehali, H., Koch, S., and Granner, D. K. (1995) Diabetes 44, 290-294 [Abstract]
  20. Whitesell, R. R., Ward, M., McCall, A. L., Granner, D. K., and May, J. M. (1995) J. Cereb. Blood Flow Metab. 15, 814-826 [Medline] [Order article via Infotrieve]
  21. Cleland, W. W. (1963) Biochim. Biophys. Acta 67, 173-188 [CrossRef][Medline] [Order article via Infotrieve]
  22. Storer, A. C., and Cornish-Bowden, A. (1976) Biochem. J. 159, 7-14 [Medline] [Order article via Infotrieve]
  23. Morita, H., Yano, Y., Niswender, K. D., May, J. M., Whitesell, R. R., Wu, L., Printz, R. L., Granner, D. K., Magnuson, M. A., and Powers, A. C. (1994) J. Clin. Invest. 94, 1373-1382 [Medline] [Order article via Infotrieve]
  24. Grossbard, L., and Schimke, R. T. (1966) J. Biol. Chem. 241, 3546-3560 [Abstract/Free Full Text]
  25. Lange, A. J., Xu, L. Z., Van Poelwijk, F., Lin, K., Granner, D. K., and Pilkis, S. J. (1991) Biochem. J. 277, 159-163 [Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.